Pictet Asset Management Holding SA Buys 18,847 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Pictet Asset Management Holding SA grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 6.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 323,552 shares of the company’s stock after acquiring an additional 18,847 shares during the period. Pictet Asset Management Holding SA owned about 0.32% of Dyne Therapeutics worth $7,623,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Norges Bank purchased a new stake in Dyne Therapeutics during the fourth quarter valued at about $22,384,000. State Street Corp lifted its stake in shares of Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after buying an additional 440,890 shares in the last quarter. RTW Investments LP boosted its holdings in Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares during the period. RA Capital Management L.P. raised its holdings in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the period. Finally, Barclays PLC lifted its position in shares of Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock worth $7,446,000 after acquiring an additional 128,246 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 4.9 %

DYN opened at $9.42 on Friday. The stock has a market capitalization of $1.07 billion, a P/E ratio of -2.65 and a beta of 1.11. Dyne Therapeutics, Inc. has a 12-month low of $8.94 and a 12-month high of $47.45. The stock has a 50-day moving average price of $12.92 and a 200-day moving average price of $22.87.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 6,237 shares of company stock worth $77,760 in the last 90 days. 20.77% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

DYN has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $47.46.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.